Repositorio UFRO · Omeka S

p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth

Primer Autor	Schillaci, Roxana
Co-autores	Tkach, Mercedes Rosemblit, Cinthia Rivas, Martin A. Proietti, Cecilia J. Diaz Flaque, Maria Celeste Florencia Mercogliano, Maria Beguelin, Wendy Maronna, Esteban Guzman, Pablo Gercovich, Felipe G. Gil Deza, Ernesto Elizalde, Patricia V.
Título	p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth
Editorial	BIOSCIENTIFICA LTD
Revista	ENDOCRINE-RELATED CANCER
Lenguaje	en
Resumen	Stat3 is a signaling node for multiple oncogenic pathways and is therefore frequently active in breast cancer. As experimental and clinical evidence reveals that progestins are key players in controlling mammary gland tumorigenesis, we studied Stat3 participation in this event. We have previously shown that progestins induce Stat3Tyr705 phosphorylation and its transcriptional activation in breast cancer cells. In this study, we demonstrate that progestins also induce Stat3 phosphorylation at Ser727 residue, which occurs via activation of c-Src/p42/p44 MAPK pathways in murine progestin-dependent C4HD cells and in T-47D cells. Expression of a Stat3S727A vector, which carries a serine-to-alanine substitution at codon 727, shows that Stat3Ser727 phosphorylation is required for full transcriptional activation of cyclin D1 gene expression by progestins and for in vivo Stat3 recruitment on cyclin D1 promoter. Transfection of Stat3S727A in murine and human breast cancer cells abolished progestin-induced in vitro and in vivo growth. Moreover, we found a positive correlation between progesterone receptor expression and nuclear localization of Stat3Ser727 phosphorylation in breast cancer biopsies. These data highlight Stat3 phosphorylation in Ser727 residue as a nongenomic action by progestins, necessary to promote breast cancer growth.
Tipo de Recurso	Artículo original
Description	This work was supported in part by the Susan G Komen for the Cure investigator-initiated research grant (KG090250 to P V Elizalde), The National Agency of Scientific Promotion of Argentina (PICT 2010 0122), The Argentina National Council of Scientific Research (PIP 737), and Oncomed-Reno CONICET (1819/03). Este trabajo fue financiado en parte por la beca de investigación iniciada por el investigador de Susan G Komen for the Cure (KG090250 a P V Elizalde), la Agencia Nacional de Promoción Científica de Argentina (PICT 2010 0122), el Consejo Nacional de Investigaciones Científicas de Argentina (PIP 737) y Oncomed-Reno CONICET (1819/03).
doi	10.1530/ERC-12-0194
Formato Recurso	pdf
Palabras Claves	Stat3 p42/p44 MAPK progestin breast cancer SIGNAL TRANSDUCER GENE-EXPRESSION TRANSCRIPTIONAL ACTIVATION CELL-LINES RECEPTOR TYROSINE PATHWAY TRANSFORMATION SELUMETINIB RESISTANCE Stat3 p42/p44 MAPK progestina cáncer de mama TRANSDUCTOR DE SEÑAL EXPRESIÓN GÉNICA ACTIVACIÓN TRANSCRIPCIONAL LÍNEAS CELULARES RECEPTOR TIROSINA VÍA TRANSFORMACIÓN SELUMETINIB RESISTENCIA
Ubicación del archivo	http://dx.doi.org/10.1530/ERC-12-0194
Materias	Stat3 p42/p44 MAPK progestin breast cancer SIGNAL TRANSDUCER GENE-EXPRESSION TRANSCRIPTIONAL ACTIVATION CELL-LINES RECEPTOR TYROSINE PATHWAY TRANSFORMATION SELUMETINIB RESISTANCE Stat3 p42/p44 MAPK progestina cáncer de mama TRANSDUCTOR DE SEÑAL EXPRESIÓN GÉNICA ACTIVACIÓN TRANSCRIPCIONAL LÍNEAS CELULARES RECEPTOR TIROSINA VÍA TRANSFORMACIÓN SELUMETINIB RESISTENCIA
Disciplinas de la OCDE	Biología Celular Biología Molecular Oncología
Título de la cita (Recomendado-único)	p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth
Revista/Libro	ENDOCRINE-RELATED CANCER
Tipo de ruta	hibrida verde
Access Rights	acceso abierto
Derechos de acceso	acceso abierto
Identificador alternativo	PMID 23329648
Idioma	en
Identificador del recurso (Mandatado-único)	Artículo original
Versión del recurso (Recomendado-único)	versión publicada
Entidad financiadora	Susan G Komen for the Cure investigator-initiated KG090250#National Agency of Scientific Promotion of Argentina (PICT) 0122#Argentina National Council of Scientific Research PIP 737#Oncomed-Reno CONICET 1819/03
Referencia del Financiador (Mandatado si es aplicable-repetible)	Susan G Komen for the Cure investigator-initiated KG090250 National Agency of Scientific Promotion of Argentina (PICT) 0122 Argentina National Council of Scientific Research PIP 737 Oncomed-Reno CONICET 1819/03
Editorial	BIOSCIENTIFICA LTD
ISSN	1351-0088
Página de inicio (Recomendado-único)	197
Página final (Recomendado-único)	212
Categoría WOS	Oncología Endocrinología y Metabolismo Oncology Endocrinology & Metabolism
Formato	pdf
Id de Web of Science	WOS:000319554600009